Emergent BioSolutions Inc. (EBS) stock
Close on Nov 17, 2026Market cap $287.64MP/E –Yield –
Earnings
Emergent BioSolutions's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.
Quarterly results
Revenue and earnings per share from each of Emergent BioSolutions's earnings releases, newest first
| Quarter | Reported | Revenue | YoY | EPS | Adj. EPS | Source |
|---|---|---|---|---|---|---|
| Q4 FY2026ended Dec 31, 2026 | Feb 25, 2027Expected | – | – | – | – | – |
| Q3 FY2026ended Sep 30, 2026 | Nov 2, 2026after the close | $110.00M | -52.4% | -$0.64 | -$0.36 | Release |
| Q2 FY2026ended Jun 30, 2026 | Aug 5, 2026after the close | $234.30M | +66.3% | -$3.49 | $0.60 | Release |
| Q1 FY2026ended Mar 31, 2026 | Apr 30, 2026after the close | $156.10M | -29.7% | $0.07 | $0.21 | Release |
| Q4 FY2025ended Dec 31, 2025 | Feb 26, 2026after the close | $148.70M | -23.6% | -$1.04 | -$0.43 | Release |
| Q3 FY2025ended Sep 30, 2025 | Oct 29, 2025after the close | $231.10M | -21.3% | $0.91 | $1.06 | Release |
| Q2 FY2025ended Jun 30, 2025 | Aug 6, 2025after the close | $140.90M | -44.7% | -$0.22 | $0.16 | Release |
| Q1 FY2025ended Mar 31, 2025 | May 7, 2025after the close | $222.20M | -26.0% | $1.19 | $0.71 | Release |
| Q4 FY2024ended Dec 31, 2024 | Mar 3, 2025after the close | $194.70M | -29.6% | -$0.58 | $0.05 | Release |
| Q3 FY2024ended Sep 30, 2024 | Nov 6, 2024after the close | $293.80M | +8.6% | $2.06 | $1.37 | Release |
| Q2 FY2024ended Jun 30, 2024 | Aug 6, 2024after the close | $254.70M | -24.6% | -$5.38 | -$2.32 | Release |
| Q1 FY2024ended Mar 31, 2024 | May 1, 2024after the close | $300.40M | +82.0% | $0.17 | $0.59 | Release |
| Q4 FY2023ended Dec 31, 2023 | Mar 6, 2024after the close | $276.60M | -16.4% | -$0.95 | -$0.77 | Release |
| Q3 FY2023ended Sep 30, 2023 | Nov 8, 2023after the close | $270.50M | +12.7% | – | – | Release |
| Q2 FY2023ended Jun 30, 2023 | Aug 8, 2023after the close | $337.90M | +39.2% | -$5.15 | -$1.06 | Release |
| Q1 FY2023ended Mar 31, 2023 | May 9, 2023after the close | $165.10M | -46.3% | -$3.65 | -$3.17 | Release |
| Q4 FY2022ended Dec 31, 2022 | Feb 27, 2023after the close | $330.70M | -54.3% | -$1.76 | -$0.31 | Release |
| Q3 FY2022ended Sep 30, 2022 | Nov 8, 2022after the close | $240.00M | -27.1% | -$1.52 | -$1.27 | Release |
| Q2 FY2022ended Jun 30, 2022 | Aug 1, 2022after the close | $242.70M | – | -$1.13 | -$0.86 | Release |
| Q1 FY2022ended Mar 31, 2022 | Apr 28, 2022after the close | $307.50M | – | -$0.07 | $0.18 | Release |
| Q4 FY2021ended Dec 31, 2021 | Feb 24, 2022after the close | $723.20M | – | $3.50 | $4.50 | Release |
| Q3 FY2021ended Sep 30, 2021 | Nov 4, 2021after the close | $329.00M | – | -$0.61 | -$0.36 | Release |
| Q2 FY2021ended Jun 30, 2021 | Jul 29, 2021after the close | – | – | – | – | Filing |
| Q1 FY2021ended Mar 31, 2021 | Apr 29, 2021after the close | – | – | – | – | Filing |
| Q4 FY2020ended Dec 31, 2020 | Jan 11, 2021before the open | – | – | – | – | Filing |
| Q3 FY2020ended Sep 30, 2020 | Nov 5, 2020after the close | – | – | – | – | Filing |
Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.
Current guidance
Emergent BioSolutions's latest outlook for periods it has not reported yet, compared with what it said before
| Metric | Period | Guidance | Before | Change | Given |
|---|---|---|---|---|---|
| Total revenues | FY2026 | $600.00M – $645.00M | – | New | Nov 2, 2026 |
| Total revenues | FY2026 | $645.00M – $675.00M | $720.00M – $760.00M | Lowered | Aug 5, 2026 |
| Adjusted gross margin %non-GAAP | FY2026 | 45% – 47% | – | New | Nov 2, 2026 |
| Adjusted gross margin %non-GAAP | FY2026 | 42% – 44% | 45% – 47% | Lowered | Aug 5, 2026 |
| Gross margin %GAAP | FY2026 | 32% – 35% | 35% – 38% | Lowered | Aug 5, 2026 |
| Adjusted EBITDAnon-GAAP | FY2026 | $110.00M – $140.00M | – | New | Nov 2, 2026 |
| Adjusted EBITDAnon-GAAP | FY2026 | $130.00M – $150.00M | $155.00M – $175.00M | Lowered | Aug 5, 2026 |
| Capex | FY2026 | $16.00M | – | New | Nov 2, 2026 |
| Capex | FY2026 | $17.00M | $17.00M | Reaffirmed | Aug 5, 2026 |
| Adjusted gross marginnon-GAAP | FY2026 | $308.00M – $341.00M | – | New | Feb 26, 2026 |
| Adjusted net incomenon-GAAP | FY2026 | $10.00M – $30.00M | $45.00M – $65.00M | Lowered | Aug 5, 2026 |
| Adjusted net income (loss)non-GAAP | FY2026 | -$10.00M – $20.00M | – | New | Nov 2, 2026 |
| Depreciation & amortization | FY2026 | $82.00M | – | Raised | Aug 5, 2026 |
| Gross marginGAAP | FY2026 | $240.00M – $273.00M | – | New | Feb 26, 2026 |
| Interest expense | FY2026 | $40.00M | – | New | Aug 5, 2026 |
| Net lossGAAP | FY2026 | -$255.00M – -$225.00M | – | New | Nov 2, 2026 |
| Net lossGAAP | FY2026 | -$245.00M – -$225.00M | – | Lowered | Aug 5, 2026 |
| R&D | FY2026 | 6% | – | New | Aug 5, 2026 |
| SG&A | FY2026 | 27% – 28% | – | Raised | Aug 5, 2026 |
| Stock-based compensation expense | FY2026 | $19.00M | – | Lowered | Aug 5, 2026 |
| Weighted avg. fully diluted share count | FY2026 | 52 | – | New | Aug 5, 2026 |
Guidance vs results
The last range Emergent BioSolutions gave before each report, against the figure it then reported. Full years add up the four quarters.
| Period | Metric | Guidance | Actual | Result |
|---|---|---|---|---|
| Q3 FY2026 | Revenue | $110.00M – $130.00M | $110.00M | Within range |
| Q2 FY2026 | Revenue | $170.00M – $185.00M | $234.30M | Above range |
| Q1 FY2026 | Revenue | $135.00M – $155.00M | $156.10M | Above range |
| FY2025 | Revenue | $775.00M – $835.00M | $742.90MΣ4Q | Below range |
| Q3 FY2025 | Revenue | $180.00M – $210.00M | $231.10M | Above range |
| Q2 FY2025 | Revenue | $95.00M – $120.00M | $140.90M | Above range |
| Q1 FY2025 | Revenue | $200.00M – $240.00M | $222.20M | Within range |
| Q3 FY2024 | Revenue | $265.00M – $315.00M | $293.80M | Within range |
| Q2 FY2024 | Revenue | $160.00M – $210.00M | $254.70M | Above range |
| Q1 FY2024 | Revenue | $200.00M – $250.00M | $300.40M | Above range |
| Q3 FY2023 | Revenue | $210.00M – $250.00M | $270.50M | Above range |
| Q2 FY2023 | Revenue | $210.00M – $230.00M | $337.90M | Above range |
| Q1 FY2023 | Revenue | $130.00M – $150.00M | $165.10M | Above range |
| Q3 FY2022 | Revenue | $230.00M – $270.00M | $240.00M | Within range |
| Q1 FY2022 | Revenue | $280.00M – $310.00M | $307.50M | Within range |
Guidance history
Every forecast Emergent BioSolutions put in an earnings release, newest first
| Given | Metric | Period | Guidance | Change |
|---|---|---|---|---|
| Nov 2, 2026 | Capex | FY2026 | $16.00M | New |
| Nov 2, 2026 | Adjusted EBITDA | FY2026 | $110.00M – $140.00M | New |
| Nov 2, 2026 | Adjusted gross margin % | FY2026 | 45% – 47% | New |
| Nov 2, 2026 | Net loss | FY2026 | -$255.00M – -$225.00M | New |
| Nov 2, 2026 | Adjusted net income (loss) | FY2026 | -$10.00M – $20.00M | New |
| Nov 2, 2026 | Total revenues | FY2026 | $600.00M – $645.00M | New |
| Aug 5, 2026 | Capex | FY2026 | $17.00M | Reaffirmed |
| Aug 5, 2026 | Adjusted EBITDA | FY2026 | $130.00M – $150.00M | Lowered |
| Aug 5, 2026 | Gross margin % | FY2026 | 32% – 35% | Lowered |
| Aug 5, 2026 | Adjusted gross margin % | FY2026 | 42% – 44% | Lowered |
| Aug 5, 2026 | Net loss | FY2026 | -$245.00M – -$225.00M | Lowered |
| Aug 5, 2026 | Weighted avg. fully diluted share count | FY2026 | 52 | New |
| Aug 5, 2026 | R&D | FY2026 | 6% | New |
| Aug 5, 2026 | SG&A | FY2026 | 27% – 28% | Raised |
| Aug 5, 2026 | Interest expense | FY2026 | $40.00M | New |
| Aug 5, 2026 | Stock-based compensation expense | FY2026 | $19.00M | Lowered |
| Aug 5, 2026 | Depreciation & amortization | FY2026 | $82.00M | Raised |
| Aug 5, 2026 | Adjusted net income | FY2026 | $10.00M – $30.00M | Lowered |
| Aug 5, 2026 | Total revenues | FY2026 | $645.00M – $675.00M | Lowered |
| Aug 5, 2026 | Total revenues | Q3 FY2026 | $110.00M – $130.00M | New |
| Apr 30, 2026 | Capex | FY2026 | $17.00M | Reaffirmed |
| Apr 30, 2026 | Adjusted EBITDA | FY2026 | $155.00M – $175.00M | New |
| Apr 30, 2026 | Adjusted gross margin % | FY2026 | 45% – 47% | New |
| Apr 30, 2026 | Adjusted net income | FY2026 | $45.00M – $65.00M | Lowered |
| Apr 30, 2026 | Total revenues | FY2026 | $720.00M – $760.00M | Raised |
| Apr 30, 2026 | Total revenues | Q2 FY2026 | $170.00M – $185.00M | New |
| Feb 26, 2026 | Capex | FY2026 | $17.00M | New |
| Feb 26, 2026 | Gross margin % | FY2026 | 35% – 38% | New |
| Feb 26, 2026 | Gross margin | FY2026 | $240.00M – $273.00M | New |
| Feb 26, 2026 | Adjusted gross margin | FY2026 | $308.00M – $341.00M | New |
| Feb 26, 2026 | Total revenues | FY2026 | $720.00M – $760.00M | New |
| Feb 26, 2026 | Product and services sales, net | FY2026 | $685.00M – $725.00M | Lowered |
| Feb 26, 2026 | Total revenues | Q1 FY2026 | $135.00M – $155.00M | New |
| Oct 29, 2025 | Capex | FY2025 | $16.00M | New |
| Oct 29, 2025 | Adjusted EBITDA | FY2025 | $195.00M – $210.00M | New |
| Oct 29, 2025 | Adjusted gross margin % | FY2025 | 52% – 54% | New |
| Oct 29, 2025 | Gross margin % | FY2025 | 43% – 46% | New |
| Oct 29, 2025 | Adjusted net income | FY2025 | $70.00M – $85.00M | New |
| Oct 29, 2025 | Net income | FY2025 | $60.00M – $75.00M | New |
| Oct 29, 2025 | Total revenues | FY2025 | $775.00M – $835.00M | New |
| Oct 29, 2025 | MCM Products | FY2025 | $450.00M – $475.00M | Lowered |
| Oct 29, 2025 | Commercial Products | FY2025 | $265.00M – $300.00M | Lowered |
| Aug 6, 2025 | Capex | FY2025 | $16.00M | Lowered |
| Aug 6, 2025 | Adjusted EBITDA | FY2025 | $175.00M – $200.00M | Raised |
| Aug 6, 2025 | Gross margin % | FY2025 | 41% – 44% | Raised |
| Aug 6, 2025 | Adjusted gross margin % | FY2025 | 50% – 52% | Raised |
| Aug 6, 2025 | Net income | FY2025 | $40.00M – $65.00M | Narrowed |
| Aug 6, 2025 | Interest expense | FY2025 | $50.00M | Lowered |
| Aug 6, 2025 | Weighted avg. fully diluted share count | FY2025 | 54 | Reaffirmed |
| Aug 6, 2025 | R&D | FY2025 | 7% – 8% | Lowered |
| Aug 6, 2025 | SG&A | FY2025 | 26% – 27% | Raised |
| Aug 6, 2025 | Depreciation & amortization | FY2025 | $100.00M | Raised |
| Aug 6, 2025 | Gross margin | FY2025 | $309.00M – $352.00M | Raised |
| Aug 6, 2025 | Adjusted net income | FY2025 | $45.00M – $70.00M | Raised |
| Aug 6, 2025 | Adjusted gross margin | FY2025 | $365.00M – $416.00M | Raised |
| Aug 6, 2025 | Total revenues | Q3 FY2025 | $180.00M – $210.00M | New |
| Aug 6, 2025 | Total revenues | FY2025 | $765.00M – $835.00M | Raised |
| Aug 6, 2025 | MCM Products | FY2025 | $440.00M – $475.00M | Lowered |
| Aug 6, 2025 | Commercial Products | FY2025 | $265.00M – $300.00M | Lowered |
| May 7, 2025 | Capex | FY2025 | $17.00M | Reaffirmed |
| May 7, 2025 | Adjusted EBITDA | FY2025 | $150.00M – $200.00M | New |
| May 7, 2025 | Gross margin % | FY2025 | 39% – 44% | Raised |
| May 7, 2025 | Adjusted gross margin % | FY2025 | 48% – 51% | New |
| May 7, 2025 | Net income | FY2025 | $20.00M – $70.00M | Lowered |
| May 7, 2025 | Adjusted net income | FY2025 | $20.00M – $70.00M | Lowered |
| May 7, 2025 | Total revenues | Q2 FY2025 | $95.00M – $120.00M | New |
| May 7, 2025 | Total revenues | FY2025 | $750.00M – $850.00M | New |
| May 7, 2025 | MCM Products | FY2025 | $435.00M – $485.00M | Lowered |
| May 7, 2025 | Commercial Products | FY2025 | $265.00M – $315.00M | Lowered |
| Mar 3, 2025 | Capex | FY2025 | $17.00M | New |
| Mar 3, 2025 | Total segment gross margin % | FY2025 | 38% – 43% | New |
| Mar 3, 2025 | R&D | FY2025 | 6% – 7% | New |
| Mar 3, 2025 | SG&A | FY2025 | 27% – 28% | Raised |
| Mar 3, 2025 | Interest expense | FY2025 | $55.00M | New |
| Mar 3, 2025 | Depreciation & amortization | FY2025 | $100.00M | Raised |
| Mar 3, 2025 | Weighted avg. fully diluted share count | FY2025 | 54 | New |
| Mar 3, 2025 | Total segment gross margin | FY2025 | $278.00M – $351.00M | New |
| Mar 3, 2025 | Total segment adjusted gross margin | FY2025 | $348.00M – $421.00M | New |
| Mar 3, 2025 | Total revenues | Q1 FY2025 | $200.00M – $240.00M | New |
| Mar 3, 2025 | Total segment revenues | FY2025 | $725.00M – $820.00M | New |
| Mar 3, 2025 | Total revenues | FY2025 | $750.00M – $850.00M | New |
| Nov 6, 2024 | Capex | FY2024 | $25.00M | Lowered |
| Nov 6, 2024 | Adjusted EBITDA | FY2024 | $180.00M – $200.00M | Raised |
| Nov 6, 2024 | Total segment adjusted gross margin % | FY2024 | 43% – 45% | Raised |
| Nov 6, 2024 | Adjusted net loss | FY2024 | -$50.00M – -$30.00M | Raised |
| Nov 6, 2024 | Net loss | FY2024 | -$203.00M – -$183.00M | Raised |
| Nov 6, 2024 | Total revenues | FY2024 | $1.07B – $1.13B | Raised |
| Aug 6, 2024 | Capex | FY2024 | $30.00M | Lowered |
| Aug 6, 2024 | Adjusted EBITDA | FY2024 | $140.00M – $180.00M | Raised |
| Aug 6, 2024 | Total segment adjusted gross margin % | FY2024 | 42% – 45% | Lowered |
| Aug 6, 2024 | Net loss | FY2024 | -$314.00M – -$274.00M | Lowered |
| Aug 6, 2024 | Adjusted net loss | FY2024 | -$115.00M – -$75.00M | Lowered |
| Aug 6, 2024 | Total revenues | Q3 FY2024 | $265.00M – $315.00M | New |
| Aug 6, 2024 | Total revenues | FY2024 | $1.05B – $1.13B | Raised |
| May 1, 2024 | Capex | FY2024 | $32.00M | New |
| May 1, 2024 | Adjusted EBITDA | FY2024 | $125.00M – $175.00M | Raised |
| May 1, 2024 | Total segment adjusted gross margin % | FY2024 | 44% – 47% | Raised |
| May 1, 2024 | Net loss | FY2024 | -$148.00M – -$98.00M | Raised |
| May 1, 2024 | Adjusted net loss | FY2024 | -$65.00M – -$15.00M | Raised |
| May 1, 2024 | Total revenues | Q2 FY2024 | $160.00M – $210.00M | New |
| May 1, 2024 | Total revenues | FY2024 | $1.00B – $1.10B | Raised |
| Mar 6, 2024 | Adjusted EBITDA | FY2024 | $50.00M – $100.00M | New |
| Mar 6, 2024 | Total segment adjusted gross margin % | FY2024 | 40% – 45% | New |
| Mar 6, 2024 | Net loss | FY2024 | -$183.00M – -$133.00M | New |
| Mar 6, 2024 | Adjusted net loss | FY2024 | -$130.00M – -$80.00M | New |
| Mar 6, 2024 | Total revenues | Q1 FY2024 | $200.00M – $250.00M | New |
| Mar 6, 2024 | Total revenues | FY2024 | $900.00M – $1.10B | New |
| Nov 8, 2023 | Adjusted EBITDA | FY2023 | -$25.00M – $75.00M | Lowered |
| Nov 8, 2023 | Adjusted Gross Margin % | FY2023 | 32% – 38% | Lowered |
| Nov 8, 2023 | Loss before income taxes | FY2023 | -$726.00M – -$626.00M | Lowered |
| Nov 8, 2023 | Total Revenues | FY2023 | $1.00B – $1.10B | Raised |
| Aug 8, 2023 | Adjusted EBITDA | FY2023 | $50.00M – $100.00M | Lowered |
| Aug 8, 2023 | Adjusted Gross Margin % | FY2023 | 36% – 39% | Lowered |
| Aug 8, 2023 | Net Loss | FY2023 | -$465.00M – -$415.00M | Lowered |
| Aug 8, 2023 | Adjusted Net Loss | FY2023 | -$195.00M – -$145.00M | Lowered |
| Aug 8, 2023 | Total Revenues | Q3 FY2023 | $210.00M – $250.00M | New |
| Aug 8, 2023 | Total Revenues | FY2023 | $1.00B – $1.10B | Raised |
| Aug 8, 2023 | Anthrax MCM | FY2023 | $200.00M – $220.00M | Lowered |
| Aug 8, 2023 | NARCAN | FY2023 | $425.00M – $445.00M | Raised |
| Aug 8, 2023 | Smallpox MCM | FY2023 | $180.00M – $200.00M | Lowered |
| Aug 8, 2023 | Other Products | FY2023 | $100.00M – $120.00M | Lowered |
| Aug 8, 2023 | CDMO | FY2023 | $60.00M – $80.00M | Lowered |
| May 9, 2023 | Adjusted EBITDA | FY2023 | $100.00M – $150.00M | Raised |
| May 9, 2023 | Adjusted Gross Margin % | FY2023 | 39% – 42% | Lowered |
| May 9, 2023 | Net Loss | FY2023 | -$185.00M – -$135.00M | Lowered |
| May 9, 2023 | Adjusted Net Loss | FY2023 | -$85.00M – -$35.00M | Lowered |
| May 9, 2023 | Total Revenues | Q2 FY2023 | $210.00M – $230.00M | New |
| May 9, 2023 | Total Revenues | FY2023 | $1.10B – $1.20B | New |
| May 9, 2023 | Anthrax MCM | FY2023 | $260.00M – $280.00M | Lowered |
| May 9, 2023 | NARCAN | FY2023 | $360.00M – $380.00M | Raised |
| May 9, 2023 | Smallpox MCM | FY2023 | $235.00M – $255.00M | Lowered |
| May 9, 2023 | Other Products | FY2023 | $120.00M – $140.00M | Lowered |
| May 9, 2023 | CDMO | FY2023 | $90.00M – $110.00M | Lowered |
| Feb 27, 2023 | Adjusted EBITDA | FY2023 | $75.00M – $125.00M | New |
| Feb 27, 2023 | Adjusted Gross Margin % | FY2023 | 41% – 44% | New |
| Feb 27, 2023 | Net Loss | FY2023 | -$180.00M – -$130.00M | New |
| Feb 27, 2023 | Adjusted Net Loss | FY2023 | -$80.00M – -$30.00M | New |
| Feb 27, 2023 | Total Revenues | Q1 FY2023 | $130.00M – $150.00M | New |
| Feb 27, 2023 | Total Revenues | FY2023 | $1.10B – $1.20B | New |
| Nov 8, 2022 | Adjusted EBITDA | FY2022 | $0 – $30.00M | Lowered |
| Nov 8, 2022 | Gross Margin | FY2022 | 33% – 34% | Lowered |
| Nov 8, 2022 | Adjusted Gross Margin | FY2022 | 39% – 41% | New |
| Nov 8, 2022 | Anthrax Vaccines | FY2022 | $260.00M – $275.00M | New |
| Nov 8, 2022 | ACAM2000 | FY2022 | $63.00M | Lowered |
| Nov 8, 2022 | TEMBEXA | FY2022 | $110.00M – $115.00M | Raised |
| Nov 8, 2022 | Nasal Naloxone Products | FY2022 | $350.00M – $365.00M | Raised |
| Nov 8, 2022 | Other Products (4) + C&G | FY2022 | $167.00M – $172.00M | Lowered |
| Nov 8, 2022 | CDMO Revenues | FY2022 | $100.00M – $110.00M | Lowered |
| Nov 8, 2022 | Adjusted Net Income (Loss) | FY2022 | -$100.00M – -$70.00M | Lowered |
| Nov 8, 2022 | Total Revenues | FY2022 | $1.05B – $1.10B | New |
| Aug 1, 2022 | Capital expenditures, net of reimbursement | FY2022 | 10% | New |
| Aug 1, 2022 | Adjusted EBITDA (2) | FY2022 | $80.00M – $120.00M | Lowered |
| Aug 1, 2022 | Gross Margin | FY2022 | 41% – 45% | Lowered |
| Aug 1, 2022 | Adjusted Net Income (Loss) (2) | FY2022 | -$15.00M – $10.00M | Lowered |
| Aug 1, 2022 | Other Products + C&G | FY2022 | $235.00M – $240.00M | Lowered |
| Aug 1, 2022 | CDMO Revenues | FY2022 | $105.00M – $125.00M | Lowered |
| Aug 1, 2022 | Total Revenues | FY2022 | $1.15B – $1.25B | Raised |
| Aug 1, 2022 | Nasal Naloxone Products | FY2022 | $300.00M – $340.00M | Raised |
| Aug 1, 2022 | Total Revenues | Q3 FY2022 | $230.00M – $270.00M | New |
| Aug 1, 2022 | Anthrax Vaccines | FY2022 | $280.00M – $300.00M | Raised |
| Aug 1, 2022 | ACAM2000 | FY2022 | $225.00M – $250.00M | Lowered |
| Apr 28, 2022 | Anthrax Vaccines | FY2022 | $280.00M – $300.00M | Lowered |
| Apr 28, 2022 | ACAM2000 | FY2022 | $190.00M – $210.00M | Lowered |
| Apr 28, 2022 | Nasal Naloxone Products | FY2022 | $240.00M – $310.00M | Raised |
| Apr 28, 2022 | Other Products + Contracts and Grants | FY2022 | $200.00M – $260.00M | Lowered |
| Feb 24, 2022 | Adjusted EBITDA | FY2022 | $240.00M – $300.00M | Lowered |
| Feb 24, 2022 | Gross Margin % | FY2022 | 47% – 51% | New |
| Feb 24, 2022 | Adjusted Net Income | FY2022 | $95.00M – $140.00M | Lowered |
| Feb 24, 2022 | total revenues | Q1 FY2022 | $280.00M – $310.00M | New |
| Feb 24, 2022 | Total Revenues | FY2022 | $1.30B – $1.40B | Lowered |
| Jan 10, 2022 | Adjusted EBITDA | FY2022 | $280.00M – $340.00M | New |
| Jan 10, 2022 | Gross Margin % | FY2022 | 47% – 51% | New |
| Jan 10, 2022 | Adjusted Net Income | FY2022 | $135.00M – $180.00M | New |
| Jan 10, 2022 | Total Revenues | FY2022 | $1.40B – $1.50B | New |
| Nov 4, 2021 | Capital expenditures, net of reimbursement | FY2021 | 8% – 9% | New |
| Nov 4, 2021 | Adjusted EBITDA | FY2021 | $500.00M – $550.00M | New |
| Nov 4, 2021 | Gross margin | FY2021 | 54% – 56% | New |
| Nov 4, 2021 | Adjusted net income | FY2021 | $315.00M – $350.00M | New |
| Nov 4, 2021 | Total revenues | FY2021 | $1.70B – $1.80B | New |
| Nov 4, 2021 | NARCAN® Nasal Spray | FY2021 | $400.00M – $420.00M | Lowered |
| Nov 4, 2021 | Anthrax vaccines | FY2021 | $250.00M – $260.00M | Lowered |
| Nov 4, 2021 | ACAM2000® | FY2021 | $200.00M – $220.00M | Lowered |
| Nov 4, 2021 | CDMO | FY2021 | $600.00M – $650.00M | Raised |
Read from the company's earnings releases; each figure links to its sentence on hover. “Raised” and “Lowered” compare with the previous range for the same metric and period.
Press releases
Releases Emergent BioSolutions filed with the SEC as exhibits to Form 8-K or 6-K
- News
- Results
- Results
- Update
- News
- Results
- Results
- Update
- Results
- Results
- Update
- Update
- Results
- Results
- Update
See a number that looks wrong?